Home | AI powered stock trade ideas | Market Signals | Breaking Out | New Green Signal Stocks | Recent Red Arrow Top Signals | Recent Green Arrow Bottom Signals | Near Term Bottom Signals | Green Stocks with Most Upside to Analyst Target Price | New Long Term Green AI Signals | Big Tech Stocks | ETF Sector SPDRs | Solar Stocks | Chip Stocks | Airline Stocks | Social Media Stocks | Oil Stocks| Discount Store Stocks | Entertainment Stocks | EV Stocks | Restaurant Stocks | Heavy Equipment Stocks | Aerospace Stocks | Home Builders | Bank Stock Signals | Cruise Ship Stock Signals | Mining Stocks | Free AI Portfolio Analyzer | How to Read and Trade AI Powered Stock Charts| Stock Charts AI top 50 Stocks

Recently Featured Stock Charts
86% AI Stock Prediction Accuracy
Enter Stock Symbol to View AI powered Stock Chart

StockChartsAI.com

All Chart Prices Delayed at least 15 minutes

Before accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.

Last Price: 3.69 - Change: -0.28 - Change %: -7.0529
05/24/2024 16:09:00 EST

CureVac NV (CVAC)

Industry: Biotechnology

Price Support Resistance

In the past 20 trading days, CVAC has been trading in a range between $3.49 and $2.52 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.

CVAC is trading between resistance at $5.41 about 47% to the upside and support at $3.59 -3% to the downside. If it can break above the resistance, it could have some more upside to the next line of resistance at $6.35, about a 72% move. If the price starts to turn down and fails to get through this level or enters a yellow zone, we would consider profit taking or exiting the position. If it enters a red zone on the chart we would exit the position.

Upside / Downside Potential

CureVac NV $CVAC entered a Green zone 12 days ago on the AI powered stock chart. Wall Street analysts have an AVG target price $14.91, a potential upside of 275.57% from the recent price of 3.97. The stock is trading 211.34% (potential upside) below its 52 week high of $12.36 and 79.64 % (potential downside) above its 52 week low of $2.21 - based on the recent price.

Company Summary

CureVac NV. , a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA).

CVAC Website

News

3 Stocks to Purge ASAP Before They're Pulled off Life Support
There are several stocks to sell now that are clinging to life support. These companies have been diluting their shares and burning cash at an alarming rate, making a successful comeback an increasingly unlikely prospect.
Source: InvestorPlace
Fri, 10 May 2024 06:36:00 -0400
Sentiment: Negative
CureVac N.V. (CVAC) Q4 2023 Earnings Call Transcript
CureVac N.V. (NASDAQ:CVAC ) Q4 2023 Earnings Conference Call April 24, 2024 9:00 AM ET Company Participants Sarah Fakih - Vice President of Corporate Communications & Investor Relations Alexander Zehnder - Chief Executive Officer Myriam Mendila - Chief Development Officer Pierre Kemula - Chief Financial Officer Marcus Dalton - Head, Intellectual Property Conference Call Participants Evan Wang - Guggenheim Roy Buchanan - Citizens JMP Mani Foroohar - Leerink Partners Umer Raffat - Evercore ISI Charlie Yang - Bank of America Operator Greetings and welcome to the CureVac Fourth Quarter and Full Year 2023 Financial Results and Business Update Conference Call.
Source: Seeking Alpha
Wed, 24 Apr 2024 15:12:02 -0400
Sentiment: Neutral
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update
Organizational redesign and rightsizing initiated across company to streamline structures, increase efficiency and reduce operating costs Together with GSK, ended Pandemic Preparedness Agreement (PPA) with Federal Republic of Germany, after consultation with the German Federal Ministry of Health Cash and cash equivalents position of €402.5 million as of December 31, 2023; cash runway extended into Q4 2025 with organizational redesign and despite PPA wind-down Strategic collaboration signed with world-leading oncology center MD Anderson, creating unique expertise to jointly discover and develop novel cancer vaccines Appointment of Thaminda Ramanayake as Chief Business Officer, bringing more than 15 years of biopharma company development and deal-making experience Promising COVID-19 and seasonal flu Phase 2 data confirms proprietary mRNA platform elicits strong overall antibody titers at well-tolerated dose levels New Phase 1/2 study in avian flu started in collaboration with GSK addressing potential future pandemic threat Successful safety review of data from glioblastoma Phase 1 Part A with multiepitope cancer vaccine candidate, CVGBM, enables progressing to Part B with expected start mid-2024 CureVac to host conference call and webcast today at 9 a.m. ET / 3 p.m.
Source: Accesswire
Wed, 24 Apr 2024 07:30:00 -0400
Sentiment: Neutral
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK
Phase 1 part of combined Phase 1/2 study initiated as part of pandemic preparedness against highly pathogenic avian influenza (H5N1) virus, considered to be potential future pandemic threat Study will assess monovalent vaccine candidate, encoding an influenza A H5-antigen using proprietary second-generation mRNA backbone Avian influenza is latest program progressing to clinical trials under broad infectious disease collaboration agreement with GSK TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 24, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the start of the Phase 1 part of a combined Phase 1/2 study of an investigational influenza A (H5N1) pre-pandemic vaccine candidate developed in collaboration with GSK.
Source: Accesswire
Wed, 24 Apr 2024 07:20:00 -0400
Sentiment: Neutral
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer
Mr. Ramanayake brings more than fifteen years of experience in biopharma company development and deal-making Strong track record of successful clinical collaborations, M&A, asset in-licensing and strategic financing initiatives across multiple therapeutic areas TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 24, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that Thaminda Ramanayake has been appointed to the role of Chief Business Officer, effective June 1, 2024.
Source: Accesswire
Wed, 24 Apr 2024 07:20:00 -0400
Sentiment: Neutral
Instituions Institution %: 21.65
Last QTR Institution change: -5671389

Insiders
Insiders %: 45.27
Insiders Purchases last QTR: 0
Insiders Sales last QTR: 0
Insiders Net last QTR: 0

Analyst Ratings
Target Price: 14.91
Overall Rating: 3.8889
Strong Buys (5): 4
Buys (4): 1
Holds (3): 3
Sells (2): 1
Strong Sells (1): 0

Technicals
52 Week Hi: 12.36
52 Week Low: 2.215
Beta: 2.508
50 Day MA: 2.9648
200 Day MA: 4.8774

Earnings / Revenue Trends
Qtr Earnings Growth YOY: 0
Qtr Revenue Growth YOY: 0.736
Forward PE: 9.1659
Trailing PE: 0

Benefits of StockChartsAI.com System:

  • Get a Daily List of Stocks Starting New Trends
  • Upload Your Stocks to Quickly See and Track Signals
  • Easy to Understand AI Stock Signals
  • Analysis of Historical Signal Trend Analysis for each stock
  • Search/View AI Stock Signals of Russel 1000 Stocks
  • Easy to Understand AI Stock Signals
  • And MUCH MUCH more!

1000

Stock Analyzed Each Night

Portfolio

Easily Upload Track Your Stocks

Trends

See Lists of Stocks Starting New Trends

The information contained on this website is solely for educational purposes, and does not constitute investment advice. The risk of trading in securities markets can be substantial. By accessing this site, you agree we are not liable, whether in contract, tort (including negligence) or otherwise, in respect of any damage, expense or other loss you may suffer arising out of such information or any reliance you may place upon such information from this site. Stocks, Futures and options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the stock, futures and options markets. Don't trade with money you can't afford to lose. This website is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this website. The past performance of any trading system or methodology is not necessarily indicative of future results. Individual results may vary, and testimonials are not claimed to represent typical results. All testimonials are by real people, and may not reflect the typical purchaser’s experience, and are not intended to represent or guarantee that anyone will achieve the same or similar results. HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY, SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.